Study of GS-0272 in Participants With Rheumatoid Arthritis

Key Inclusion Criteria: * Age limit for the Republic of Korea for male or nonpregnant female is between 19 and 75 years of age. Part A (Rheumatoid Arthritis (RA) Cohorts)-Specific Inclusion Criteria: * Diagnosis of RA at least 3 months prior to screening fulfilling the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria. * Ongoing treatment with 1 or 2 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for at least 12 weeks prior to the first dose of study drug, with a stable dose for at least 4 weeks prior to the first dose of study drug, as follows: * Individuals must not be on a biologic disease-modifying antirheumatic drugs (bDMARD)/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) at Day 1 or during the study and must discontinue b/tsDMARD use for at least 4 weeks (with the exception of rituximab, which must be discontinued for at least 16 weeks) prior to the first dose of study drug. Part B (Active RA Cohort)-Specific Inclusion Criteria: * Participant is seropositive as demonstrated by a positive anti-cyclic citrullinated peptide (anti-CCP) antibody and/or positive rheumatoid factor at screening. * Participant has an elevated high-sensitivity C-reactive protein (hsCRP) greater than upper limit of normal (ULN). * Participant has 6 or more swollen and 6 or more tender joints as assessed on the SJC66/TJC68. Distal interphalangeal joints will not be counted towards the 6 joi…